Pharmaceutical Contract Development and Manufacturing Market Size, Share, Growth Analysis, By Service(Pharmaceutical Manufacture, Drug Development, And Biologics Manufacturing.), By End user(Large pharmaceutical firms, small & mid-size pharmaceutical companies, and generic pharmaceutical companies.), By Region - Industry Forecast 2024-2031

Pharmaceutical Contract Development and Manufacturing Market size was valued at USD 114.36 billion in 2019 and is poised to grow from USD 122.25 billion in 2023 to USD 222.87 billion by 2031, growing at a CAGR of 6.9% in the forecast period (2024-2031).

Pharmaceutical contract development and manufacturing firms provide a range of services to small and large pharmaceutical enterprises under a contract. These services include the production of final dosage forms (FDFs), active ingredients (APIs), drug research & drug discovery services, and biologics. Manufacturers' increasing propensity to use cutting-edge technologies, the expiration of drug patents, rising investments in R&D, the rise in demand for generic medications & biologics, and the COVID-19 pandemic are all factors that have contributed to the growth of the market. Additionally, the market is anticipated to expand because of the rising need for cell and gene treatments, customised medicines, high potency active pharmaceutical ingredients (HPAPIs), and antibody-drug conjugates (ADCs). The adoption of serialisation and a dearth of qualified specialists are two obstacles to this market's expansion, nevertheless.

US Pharmaceutical Contract Development and Manufacturing Market is poised to grow at a sustainable CAGR for the next forecast year.